TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Mayne Pharma Group ( (AU:MYX) ).
Mayne Pharma has announced an update on its proposed acquisition by Cosette Pharmaceuticals, with the Foreign Investment Review Board extending its approval deadline to November 21, 2025. The company has rescheduled the court hearing to approve the scheme of arrangement to November 23, 2025. The acquisition remains contingent on FIRB and court approvals, among other conditions. If approved, Mayne Pharma shares will be suspended from trading on November 24, 2025, marking a significant shift in its market presence.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma is an ASX-listed specialty pharmaceutical company that focuses on commercializing novel pharmaceuticals to provide safer and more accessible medicines. It is a leader in dermatology and women’s health in the United States and offers contract development and manufacturing services globally. With a 40-year history of innovation, Mayne Pharma has successfully developed and commercialized new oral drug delivery systems.
Average Trading Volume: 458,975
Technical Sentiment Signal: Sell
Current Market Cap: A$389.2M
For detailed information about MYX stock, go to TipRanks’ Stock Analysis page.